Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1973 Nov;52(11):2708–2716. doi: 10.1172/JCI107465

Quantitative Assay of a Plasma Factor Deficient in von Willebrand's Disease that is Necessary for Platelet Aggregation. RELATIONSHIP TO FACTOR VIII PROCOAGULANT ACTIVITY AND ANTIGEN CONTENT

Harvey J Weiss 1,2,3, Leon W Hoyer 1,2,3, Frederick R Rickles 1,2,3, André Varma 1,2,3, John Rogers 1,2,3
PMCID: PMC302537  PMID: 4542944

Abstract

In a previous paper, we showed that the abnormality of ristocetin-induced platelet aggregation in platelet-rich plasma in 10 patients with von Willebrand's disease could be corrected by a factor in normal plasma that was present in the same fractions as factor VIII procoagulant activity (antihemophilic factor, AHF, VIIIAHF) when prepared by chromatography on Bio-Gel 5 M (Bio-Rad Laboratories, Richmond, Calif.). This observation suggests that patients with this disorder are deficient in a plasma factor, associated with the factor VIII molecule, that is necessary for normal platelet function. In the present paper, we describe, an assay for this factor, the von Willebrand factor (VIIIVWF), based on the observation that a log-log relationship exists between the amount of ristocetin-induced aggregation of washed, normal platelets and the concentration of normal plasma present in the test system. We assayed the activity of VIIIVWF as well as antihemophilic factor procoagulant activity (VIIIAHF) and factor VIII antigen (VIIIAGN) in 15 patients with von Willebrand's disease and 20 normal subjects. A highly significant correlation (r ∼ 0.80) between VIIIVWF and both VIIIAHF was found in normal subjects and in patients with von Willebrand's disease. This finding, in addition to the observation that agarose gel chromatography fractions that have VIIIAHF procoagulant activity also have VIIIVWF activity, strongly suggests that the von Willebrand factor is associated with the factor VIII molecule. VIIIVWF in normal plasma was not inhibited by human anti-VIII, and VIIIVWF levels were normal in hemophilic plasma. Thus, the VIIIVWF site on the factor VIII molecule appears to be different from that determining VIIIAHF. Finally, the activity of VIIIVWF appeared to correlate better with the bleeding time than either VIIIAHF or VIIIAGN. This suggests that VIIIVWF assayed in this study may be the “anti-bleeding factor” that is deficient in von Willebrand's disease. These findings are consistent with a decreased synthesis of the factor VIII molecule in von Willebrand's disease and suggest the possibility of additional abnormalities of the site on the molecule that determines the activity of VIIIVWF.

Full text

PDF
2708

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett B., Ratnoff O. D., Levin J. Immunologic studies in von Willebrand's disease. Evidence that the antihemophilic factor (AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia. J Clin Invest. 1972 Oct;51(10):2597–2601. doi: 10.1172/JCI107077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bouma B. N., Wiegerinck Y., Sixma J. J., Van Mourik J. A., Mochtar I. A. Immunological characterization of purified anti-haemophilic factor A (factor VIII) which corrects abnormal platelet retention in Von Willebrand's disease. Nat New Biol. 1972 Mar 29;236(65):104–106. doi: 10.1038/newbio236104a0. [DOI] [PubMed] [Google Scholar]
  3. CORNU P., LARRIEU M. J., CAEN J., BERNARD J. Transfusion studies in von Willebrand's disease: effect on bleeding time and factor VIII. Br J Haematol. 1963 Apr;9:189–202. doi: 10.1111/j.1365-2141.1963.tb05457.x. [DOI] [PubMed] [Google Scholar]
  4. CORNU P., LARRIEU M. J., CAEN J., BERNARD J. Transfusion studies in von Willebrand's disease: effect on bleeding time and factor VIII. Br J Haematol. 1963 Apr;9:189–202. doi: 10.1111/j.1365-2141.1963.tb05457.x. [DOI] [PubMed] [Google Scholar]
  5. Hershgold E. J., Davison A. M., Janszen M. E. Isolation and some chemical properties of human factor VIII (antihemophilic factor). J Lab Clin Med. 1971 Feb;77(2):185–205. [PubMed] [Google Scholar]
  6. Holmberg L., Nilsson I. M. Genetic variants of von Willebrand's disease. Br Med J. 1972 Aug 5;3(5822):317–320. doi: 10.1136/bmj.3.5822.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Howard M. A., Firkin B. G. Ristocetin--a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh. 1971 Oct 31;26(2):362–369. [PubMed] [Google Scholar]
  8. Hoyer L. W. Immunologic studies of antihemophilic factor (AHF, factor VIII). 3. Comparative binding properties of human and rabbit anti-AHF. Blood. 1972 Apr;39(4):481–489. [PubMed] [Google Scholar]
  9. Hoyer L. W. Immunologic studies of antihemophilic factor (AHF, factor VIII). IV. Radioimmunoassay of AHF antigen. J Lab Clin Med. 1972 Dec;80(6):822–833. [PubMed] [Google Scholar]
  10. Kass L., Ratnoff O. D., Leon M. A. Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A. J Clin Invest. 1969 Feb;48(2):351–358. doi: 10.1172/JCI105991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. NILSSON I. M., BLOMBACK M., VON FRANCKEN I. On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand. 1957 Oct 30;159(1):35–57. doi: 10.1111/j.0954-6820.1957.tb00532.x. [DOI] [PubMed] [Google Scholar]
  12. Perkins H. A. Correction of the hemostatic defects in Von Willebrand's disease. Blood. 1967 Sep;30(3):375–380. [PubMed] [Google Scholar]
  13. SALZMAN E. W. MEASUREMENT OF PLATELET ADHESIVENESS. A SIMPLE IN VITRO TECHNIQUE DEMONSTRATING AN ABNORMALITY IN VON WILLEBRAND'S DISEASE. J Lab Clin Med. 1963 Nov;62:724–735. [PubMed] [Google Scholar]
  14. Schmer G., Kirby E. P., Teller D. C., Davie E. W. The isolation nd characterization of bovine factor VIII (antihemophilic factor). J Biol Chem. 1972 Apr 25;247(8):2512–2521. [PubMed] [Google Scholar]
  15. Stites D. P., Hershgold E. J., Perlman J. D., Fudenberg H. H. Factor 8 detection by hemagglutination inhibition: hemophilia A and von Willebrand's disease. Science. 1971 Jan 15;171(3967):196–197. doi: 10.1126/science.171.3967.196. [DOI] [PubMed] [Google Scholar]
  16. THELIN G. M., WGNER R. H. Sedimentation of plasma antihemophilic factor. Arch Biochem Biophys. 1961 Oct;95:70–76. doi: 10.1016/0003-9861(61)90110-2. [DOI] [PubMed] [Google Scholar]
  17. Weiss H. J., Kochwa S. Molecular forms of antihaemophilic globulin in plasma, cryoprecipitate and after thrombin activation. Br J Haematol. 1970 Jan;18(1):89–100. doi: 10.1111/j.1365-2141.1970.tb01421.x. [DOI] [PubMed] [Google Scholar]
  18. Weiss H. J., Phillips L. L., Rosner W. Separation of sub-units of antihemophilic factor (AHF) by agarose gel chromatography. Thromb Diath Haemorrh. 1972 Apr 30;27(2):212–219. [PubMed] [Google Scholar]
  19. Weiss H. J., Rogers J., Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest. 1973 Nov;52(11):2697–2707. doi: 10.1172/JCI107464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Weiss H. J., Rogers J., Brand H. Properties of the platelet retention (von Willebrand) factor and its similarity to the antihemophilic factor (AHF). Blood. 1973 Jun;41(6):809–815. [PubMed] [Google Scholar]
  21. Weiss H. J., Rogers J. Correction of the platelet abnormality in von Willebrand's disease by cryoprecipitate. Am J Med. 1972 Dec;53(6):734–738. doi: 10.1016/0002-9343(72)90190-8. [DOI] [PubMed] [Google Scholar]
  22. Weiss H. J. Von Willebrand's disease--diagnostic criteria. Blood. 1968 Oct;32(4):668–679. [PubMed] [Google Scholar]
  23. Zimmerman T. S., Ratnoff O. D., Powell A. E. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971 Jan;50(1):244–254. doi: 10.1172/JCI106480. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES